ReviewFrontiers in oncology2026
Perioperative care of patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Patients with chronic myeloid leukemia (CML) are increasingly undergoing surgical procedures as long-term survival improves with tyrosine kinase inhibitor (TKI) therapy. This narrative review aims to synthesize current evidence regarding perioperative risk assessment and management in patients with CML receiving TKIs. Methods: A literature search was conducted using structured searches of PubMed, Scopus, Web of Science, and Google Scholar for studies addressing perioperative management, anesthesia, bleeding, thrombosis, wound healing, obesity, pregnancy, and drug interactions in CML. Original studies, retrospective cohorts, case series, case reports, and narrative reviews relevant to perioperative care were included. Results: Available evidence demonstrated that perioperative risk in CML extends beyond routine hematologic parameters and is strongly influenced by TKI-specific toxicities and disease-related factors. Dasatinib showed the greatest association with platelet dysfunction and cytopenias, while nilotinib and ponatinib were linked to increased arterial and cardiovascular risk. Splenomegaly, obesity, bariatric surgery, and pregnancy further altered perioperative risk and TKI pharmacokinetics. Available evidence does not establish validated drug-specific preoperative TKI interruption intervals, and the decision regarding temporary interruption should therefore be individualized according to TKI-specific toxicity, disease status, and procedural risk. The review additionally identified clinically significant CYP3A4-mediated interactions with perioperative anesthetic, antimicrobial, and analgesic agents, suggesting preferential use of propofol-based induction and non-CYP-dependent opioids when feasible. Conclusions: Perioperative management in CML requires individualized multidisciplinary planning integrating hematologic, anesthetic, surgical, and pharmacologic considerations to optimize surgical safety while maintaining disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.